✅ FACT CHECK: Life Biosciences’ First Human Trial of Epigenetic “Age‑Resetting” Gene Therapy

✔️ Claim 1 — “The first human trial of a powerful new gene therapy to ‘reset’ cell age developed by Life Biosciences has been approved.”

True.
Multiple independent 2026 reports confirm that the U.S. FDA has cleared Life Biosciences’ Investigational New Drug (IND) application for ER‑100, allowing the first-ever human trial of a partial epigenetic reprogramming therapy.
[markets.bu...nsider.com], [longevity.technology], [nad.com]

✔️ Claim 2 — “The FDA approved a first human trial of a gene therapy developed by Life Biosciences, co‑founded by Harvard scientist David Sinclair.”

True.
Reports explicitly state that Life Biosciences was co‑founded by Harvard geneticist David Sinclair, and that the FDA has approved ER‑100 to proceed to human trials.
[markets.bu...nsider.com], [aol.com], [nad.com]

✔️ Claim 3 — “The therapy aims to ‘reset’ the age of cells and will first be tested in patients with certain types of vision loss.”

True.
ER‑100 uses partial epigenetic reprogramming (OSK factors) to restore a more youthful epigenetic state and is being tested in patients with open‑angle glaucoma and NAION.
[interestin...eering.com], [markets.bu...nsider.com], [longevity.technology]

✔️ Claim 4 — “The official purpose is not treating aging, because the FDA does not classify aging as a disease.”

True.
Reports emphasize that while ER‑100 is based on aging biology concepts, the FDA approval is strictly for optic neuropathies, not aging itself.
[jdsupra.com]

✔️ Claim 5 — “Trial indications: glaucoma and NAION, diseases that damage the optic nerve.”

True.
All major sources confirm that the Phase 1 trial enrolls patients with glaucoma and NAION, both optic neuropathies involving retinal ganglion cell loss.
[markets.bu...nsider.com], [interestin...eering.com]

✔️ Claim 6 — “Sinclair’s 1990s theory: aging is partly caused by loss of epigenetic information.”

True.
Coverage highlights Sinclair’s Information Theory of Aging, originating in the 1990s, focusing on loss/damage of epigenetic control.
[nad.com]

✔️ Claim 7 — “Gene therapy delivers three specific proteins identified in Sinclair’s lab to reset epigenetic information.”

True.
ER‑100 uses three of the four Yamanaka factors — OCT4, SOX2, KLF4 (OSK) — selected and refined in Sinclair-associated research, to reset epigenetic markers without full dedifferentiation.
[interestin...eering.com], [markets.bu...nsider.com]

✔️ Claim 8 — “Sinclair said it took 30+ years to reach this point.”

True.
A 2026 report quotes Sinclair saying: “It’s been over 30 years to get to this point…” referring to the journey toward human testing.
[nad.com]

✔️ Claim 9 — “Source: MIT Technology Review”

True.
MIT Technology Review published a January 27, 2026 article confirming FDA approval and describing Sinclair’s involvement and the upcoming trial.
[technologyreview.com]

📌 Overall Verdict: The summary is accurate.

Every major claim in your summary is factually supported by multiple reputable 2026 sources:

• FDA approval of the first human trial
• Use of epigenetic reprogramming (OSK factors)
• Focus on glaucoma and NAION
• Sinclair’s aging theory background
• Not positioned as an “anti-aging” trial due to FDA rules
• Statements attributed to Sinclair
• Confirmation via MIT Technology Review